Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Axis Clinicals LLC

Neither a doctor nor a teaching hospital

Research payments

$5,896,150

100 payments

Through program year 2025, Axis Clinicals LLC is reported as receiving $5,896,150 in research payments, across 100 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,196,345 64
2024 Research $188,211 7
2023 Research $2,538,241 6
2022 Research $86,730 1
2021 Research $1,495,153 18
2019 Research $391,470 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $3,544,794 6 payments
  2. Eiger BioPharmaceuticals, Inc. $1,495,153 18 payments
  3. Scilex Pharmaceuticals Inc. $391,470 4 payments
  4. Amgen Inc. $313,345 2 payments
  5. Sanofi US Services Inc. $89,082 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $23,441 4 payments
  7. AbbVie, Inc. $19,934 1 payment
  8. Boehringer Ingelheim International GmbH $18,932 60 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using Investigational 1-Ml and 2-Ml Prefilled Syringes and Mirikizumab Test Solution Formulation Using Investigational 1-Ml and 2-Ml Prefilled Syringes in Healthy Participants $1,337,277 2 payments
  2. A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using An Investigational 1-Ml Autoinjector and Mirikizumab Test Solution Formulation Using An Investigational 1-Ml Autoinjector in Healthy Participants $1,176,479 1 payment
  3. A Phase 1, Double-Blind, Two-Arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity Or Overweight, Without Diabetes $944,308 2 payments
  4. Lnf-020 $865,643 9 payments
  5. Lnf-021 $629,510 9 payments
  6. Pk-005 $201,120 2 payments
  7. Adh-004 $190,350 2 payments
  8. A Phase 1, Open-label, Drug-Drug Interaction Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple CYP450 Substrates in Patients With Moderate to Severe Atopic Dermatitis $186,255 1 payment
  9. AMG 451 DDI/Atopic Dermatitis $127,090 1 payment
  10. A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using An Investigational 1-Ml Autoinjector and Mirikizumab Test Solution Formulation Using An Investigational 1-Ml Autoinjector in Healthy Participants $86,730 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $1,066,241 4 payments
  2. Other $588,045 8 payments
  3. Overhead $141,318 4 payments
  4. Non-patient care $91,019 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record